Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Salarius Pharmaceuticals ( (SLRX) ) just unveiled an update.
On January 7, 2026, Salarius Pharmaceuticals announced it would change its corporate name to Decoy Therapeutics Inc., effective January 8, 2026, and that its Nasdaq ticker will switch from SLRX to DCOY on the same date, with accompanying updates to its corporate charter, bylaws and website; the company emphasized that these changes will not affect shareholders’ rights, share count, CUSIP, transfer agent, operations or leadership. The rebranding underscores a strategic focus on an AI-enabled, peptide-conjugate drug platform aimed at high-priority viral and oncology targets, with a 2026 plan centered on advancing its lead antiviral toward the clinic, broadening its preclinical pipeline, pursuing non-dilutive funding and strategic partnerships, and seeking to strengthen its capital structure and investor visibility.
The most recent analyst rating on (SLRX) stock is a Hold with a $0.81 price target. To see the full list of analyst forecasts on Salarius Pharmaceuticals stock, see the SLRX Stock Forecast page.
Spark’s Take on SLRX Stock
According to Spark, TipRanks’ AI Analyst, SLRX is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and negative free cash flow) and a clearly bearish price trend versus key moving averages. Valuation provides limited offset because losses make P/E less meaningful and no dividend yield is available.
To see Spark’s full report on SLRX stock, click here.
More about Salarius Pharmaceuticals
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, is a preclinical-stage biotechnology company developing next-generation peptide-conjugate therapeutics. Leveraging machine learning, AI tools and high-speed synthesis, the company targets serious unmet medical needs, with an initial pipeline focused on respiratory viruses such as pan-coronavirus, influenza and RSV, as well as gastrointestinal cancers, and has attracted backing from institutional investors and specialized life sciences and technology-oriented funding programs.
Average Trading Volume: 1,942,669
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.15M
For detailed information about SLRX stock, go to TipRanks’ Stock Analysis page.